Astellas Pharma Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALPMY Over the counter 2834 www.astellas.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Astellas Pharma Inc.

Lilly shuffles business structure; Novartis writes off part of Avidity deal - Oct 28th, 2026 7:27 am
Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal - Oct 28th, 2026 6:06 am
Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology - Oct 27th, 2026 5:30 pm
New Canadian Real-World Evidence at ESMO 2026 Highlights Integration of CLDN18.2 Testing and Targeted Treatment in Clinical Practice - Oct 26th, 2026 7:00 am
AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million - Oct 21st, 2026 6:00 am
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year? - Oct 19th, 2026 6:40 am
Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight - Oct 13th, 2026 8:31 am
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer - Oct 8th, 2026 6:30 am
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026 - Oct 6th, 2026 5:30 pm
New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes - Oct 2nd, 2026 6:00 am
Astellas Pharma Inc's Dividend Analysis - Sep 29th, 2026 5:11 am
ARTHEx Biotech Announces Appointment of Glenn P. Sblendorio as Chairman of the Board - Sep 29th, 2026 1:00 am
Astellas Pharma (TSE:4503) Stock Could Be 39% Below Fair Value On Cash Flow - Sep 26th, 2026 12:09 pm
Astellas lists 431K sf Northbrook HQ in possible sale-leaseback play - Sep 24th, 2026 9:24 am
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer - Sep 23rd, 2026 5:30 pm
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President - Sep 2nd, 2026 4:00 pm
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - Sep 1st, 2026 10:35 am
Mid-cap biotechs join Trump’s latest round of drug pricing deals - Sep 1st, 2026 6:14 am
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push - Sep 1st, 2026 6:05 am
Trump's Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing - Aug 31st, 2026 7:59 pm